RNAi Win in ATTR-CM; HF Congestion Monitor Approved; Lp(a) & In-Stent Restenosis

Source link :

Vutrisiran (Amvuttra), an RNA-interfering (RNAi) therapy, reduced hard events and disease progression in transthyretin amyloidosis cardiomyopathy (ATTR-CM) regardless of background tafamidis (Vyndamax, Vyndaqel) therapy, according to HELIOS-B phase III study results announced by Alnylam Pharmaceuticals. Aspirin remains widely used in the U.S. for primary and secondary prevention despite its prevalence drifting downward from 2012 to […]

Author : News Health

Publish date : 2024-06-25 18:35:06

Copyright for syndicated content belongs to the linked Source.